Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus Docetaxel in Advanced Lung Adenocarcinoma
NCT02668393Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Primary completion
- Nov 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of nintedanib in lung adenocarcinoma (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-limiting Toxicity at 28 days. Started Mar 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02668393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02668393.